Novo Nordisk is dropping its lawsuit against Hims & Hers Health, as it has reached an agreement with the telehealth company. The deal will permit Hims & Hers Health to sell Ozempic and Wegovy on its ...

First approved for treating diabetes in late 2017, Novo Nordisk's (NYSE: NVO) GLP-1 drug Ozempic didn't really take off until about 2021, with the addition of a version tailored to weight loss, called ...

The manufacturer of popular weight-loss drugs Ozempic and Wegovy, Novo Nordisk, is taking heat from the federal government for regularly failing to report potential side effects of its GLP-1 ...

Novo Nordisk has started building its first brand-new manufacturing facility in Denmark since the millennium, saying it plans to spend around DKK 8.5 billion ($1.2 billion) on the plant. The new site ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Novo Nordisk and Hims & ...

Wegovy maker Novo Nordisk said it is teaming up with Hims & Hers Health to sell its weight-loss drugs through the telehealth company’s platform, bringing an end to a legal dispute between the two ...

Novo Nordisk's new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay ...

CagriSema shows 23% weight loss versus 25.5% for Zepbound Novo's shares drop 15% Lilly's shares rise 4% in US pre-market trading Outcome is 'worst-case scenario' for Novo, investor says Few analysts ...

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.

Feb 23 (Reuters) - Novo Nordisk shares slumped by more than 16% on Monday, wiping away the remaining ‌gains brought by its blockbuster weight-loss drug Wegovy, ‌after the drugmaker said its ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration issued a warning letter to Novo Nordisk earlier this month, citing the company's failure to ...

COPENHAGEN, March 10 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Tuesday it had received a warning letter from the U.S. Food and Drug Administration regarding an inspection at the ...